Hutchmed (China) Limited shares fall 5.09% premarket despite interim profit jump.

Hutchmed (China) Limited fell 5.09% in premarket trading. The company reported a jump in profit during the first half of its current financial year, driven by a one-off gain on the disposal of a 45% stake in Shanghai Hutchison Pharmaceuticals. However, Hutchmed forecasts a full-year decline in its key Oncology/Immunology segment, which may have contributed to the stock's decline. Additionally, the company announced that it has received Chinese regulatory approval for a combination of two drugs to treat non-small cell lung cancer, which could be seen as a positive development for the company's oncology portfolio.